In Merck’s case, worries over rising competition from so-called ‘biosimilar’ generic products, which approximate the biological chemical structure of branded medicines, is behind much of the ...

Its precious metal holdings are on a tear and there should be material gains from its two largest unlisted investments, too ...

The macroeconomic environment looks to have turned against top dividend payers BP and Shell, raising questions about their new strategies ...

The tone of this week’s spending review was set days before the event itself when one of Labour’s bolder attempts to demonstrate its commitment to fiscal responsibility – axing the winter fuel payment ...